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ingle High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent
r Bare-Metal Stent in Acute Myocardial Infarction Study) Trials
cot Garg, MB, CHB,* Giovanna Sarno, MD, PHD,* Patrick W. Serruys, MD, PHD,*
lfredo E. Rodriguez, MD, PHD,‡ Leonardo Bolognese, MD,§ Maurizio Anselmi, MD,
icoletta De Cesare, MD,¶ Salvatore Colangelo, MD,# Raul Moreno, MD,‡‡
tefania Gambetti, BSC,** Monia Monti, BSC,** Laura Bristot, BSC,** Marco Bressers, MSC,†
ector M. Garcia-Garcia, MD, PHD,† Giovanni Parrinello, PHD,†† Gianluca Campo, MD,**
arco Valgimigli, MD, PHD,** on behalf of the STRATEGY and MULTISTRATEGY
nvestigators
otterdam, the Netherlands; Buenos Aires, Argentina; Arezzo, Verona, Pavia, Turin, Ferrara,
rescia, Italy; and Madrid, Spain
bjectives This study sought to evaluate the impact of SYNTAX score (SXscore), and compare its
erformance in isolation and combination with the PAMI (The Primary Angioplasty in Myocardial
nfarction Study) score, for the prediction of 1-year clinical outcomes in patients with ST-segment
levation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
ackground Patients with STEMI were excluded from the original SYNTAX score (SXscore) algorithm.
herefore, the utility of using the SXscore in this patient group remains undeﬁned.
ethods SXscore was calculated retrospectively in 807 patients with STEMI enrolled in the random-
zed STRATEGY (Single High-Dose Bolus Tiroﬁban and Sirolimus-Eluting Stent Versus Abciximab and
are-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Sin-
le High-Dose Bolus Tiroﬁban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in
cute Myocardial Infarction Study) clinical trials. Clinical outcomes of all-cause death, reinfarction,
nd clinically driven target vessel revascularization were subsequently stratiﬁed according to SXscore
ertiles: SXLOW 9 (n  311), 9  SXMID 16 (n  234), SXHIGH 16 (n  262).
esults At 1-year follow-up, all clinical outcomes including mortality, mortality/reinfarction, major
dverse cardiac events (MACE) (a composite of all-cause death, reinfarction and target vessel revas-
ularization), and deﬁnite, deﬁnite/probable, and any stent thrombosis were all signiﬁcantly higher
n patients in the highest SXscore tertile. SXscore was identiﬁed as an independent predictor of
ortality, MACE, and stent thrombosis out to 1-year follow-up. The combination SYNTAX-PAMI score
ed to a net reclassiﬁcation improvement of 15.7% and 4.6% for mortality and MACE, respectively.
he C-statistics for the SXscore, PAMI score, and the combined SYNTAX-PAMI score were 0.65, 0.81,
nd 0.73 for 1-year mortality, and 0.68, 0.64, and 0.69 for 1-year MACE, respectively.
onclusions SXscore does have a role in the risk stratiﬁcation of patients with STEMI having pri-
ary percutaneous coronary intervention; however, this ability can be improved through a combi-
ation with clinical variables. (Multicentre 22 Factorial Randomised Study Comparing Tiroﬁban Ver-
us Abciximab and SES Versus BMS in AMI; NCT00229515) (J Am Coll Cardiol Intv 2011;4:66–75)
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67urrently, several validated patient-based risk scores are in
se in patients presenting with ST-segment elevation myo-
ardial infarction (STEMI) (1–5). Most of these scores,
part from the Zwolle and CADILLAC (Controlled Ab-
iximab and Device Investigation to Lower Late Angio-
lasty Complications) scores, rely entirely on patient-based
ariables such as Killip class, serum creatinine levels, and
egree of ST-segment change. This is not surprising given
hese models were developed before the widespread use of
rimary percutaneous coronary intervention (PCI) for the
reatment of STEMI. Overall, the individual ability of these
cores to predict mortality is somewhat variable (6), and a
otable limitation is the absence of any assessment of lesion
haracteristics.
The SYNTAX score (SXscore) is an angiographic scoring
ystem that has been shown to be able to aid revasculariza-
ion decisions, and predict mortality and morbidity in
atients irrespective of disease severity, at both short- and
ong-term follow-up (7–15). These previous assessments
f the SXscore have been largely limited to elective
atients. At present, therefore, the SXscore has not been
alidated in patients with STEMI, and as such, the utility
f risk stratifying these patients using the SXscore remains
nknown.
The objective of this study was to assess the impact of the
Xscore and compare its performance in isolation, and in
ombination, with an entirely clinical-based score, the PAMI
Primary Angioplasty in Myocardial Infarction) study score,
or the prediction of 1-year clinical outcomes in patients
ith STEMI treated with primary PCI, who were enrolled
n the prospective randomized STRATEGY (Single High
ose Bolus Tirofiban and Sirolimus Eluting Stent Versus
bciximab and Bare-Metal Stent in Myocardial Infarction)
16) and MULTISTRATEGY (Multicenter Evaluation of
ingle High-Dose Bolus Tirofiban Versus Abciximab With
irolimus-Eluting Stent or Bare-Metal Stent in Acute
yocardial Infarction) (17) studies.
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otterdam, the Netherlands; †Cardialysis, Rotterdam, the Netherlands; ‡Department
f Cardiology, Otamendi Hospital, Buenos Aires, Argentina; §Cardiovascular De-
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tudy population. The STRATEGY and MULTISTRAT-
GY studies have been published previously (16,17). In
rief, the single-center prospective STRATEGY study
andomized 175 patients to treatment with either tirofiban
nd sirolimus-eluting stents (SES) or abciximab and bare-
etal stents (BMS), whereas the multicenter MULTI-
TRATEGY study randomized 745 patients between an
nfusion of either tirofiban or abciximab and stenting with
ither a SES or BMS.
atient selection. Inclusion and exclusion criteria were sim-
lar for both studies. Patients presenting with STEMI who
ad: 1) chest pain for 30 min with ST-segment elevation
f 1 mm in 2 contiguous electrocardiographic leads
r with presumably new left bundle-branch block; and
) admission either 12 h of
ymptom onset or between 12
nd 24 h with evidence of con-
inuing ischemia were eligible
or enrollment. Exclusion crite-
ia included administration of
brinolytic agents in the previ-
us 30 days, history of bleeding
iathesis or allergy to the study
rugs, major surgery within 15
ays, and active bleeding or pre-
ious stroke in the last 6 months.
he institutional review board at
ach participating center approved
he protocol, and all patients gave
ritten informed consent.
andomization and procedure.
etail information regarding the
andomization procedure for
oth studies is provided else-
here (16,17). In brief, before
ngiography open-label 1:1 and
:1:1:1 randomization was per-
ormed in the STRATEGY and MULTISTRATEGY
tudies, respectively. In STRATEGY, patients were ran-
omized to an infusion of tirofiban and then PCI with SES
r an infusion of abciximab followed by PCI with BMS. In
ULTISTRATEGY, patients were randomized to an
nfusion of tirofiban or abciximab followed by PCI with
ither SES or BMS. Tirofiban and abciximab were admin-
stered before sheath insertion. Crossover to a BMS was
nly allowed when SES implantation failed or when it was
mpossible to match SES diameter with coronary reference
iameter.
Details of angiographic and electrocardiographic analysis
ogether with dosage regimes of the parenteral periproce-
ural anticoagulants heparin, tirofiban, and abciximab are
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
IRA  infarct-related artery
MACE  major adverse
cardiac event(s)
PCI  percutaneous
coronary intervention
ROC  receiver-operator
characteristic
SES  sirolimus-eluting
stent(s)
ST  stent thrombosis
STEMI  ST-segment
elevation myocardial
infarction
SXscore  SYNTAX score
TIMI  Thrombolysis In
Myocardial Infarction
TVR  target vessel
revascularizationrovided elsewhere (16,17). All patients received aspirin
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68Figure 1. Schematic Diagram Indicating the Different Scoring Methods Used to Calculate the SYNTAX Score of the Culprit Lesion
Each culprit lesion was scored using Method A, where the lesion SYNTAX score was calculated before any instrumentation of the vessel, and then using Method
B, where the lesion SYNTAX score was calculated using the angiographic ﬁlm just before stent implantation. In this example, both images are of the same lesion
in the left anterior descending artery; on the initial angiographic ﬁlms (top) the left anterior descending artery was occluded, following wiring, and before dila-
tion (bottom), an open vessel was seen with an underlying bifurcation lesion. Therefore, the lesion was scored as an acute occlusion using Method A, and a
bifurcation lesion using Method B. The results of the scores calculated using Method B are available in the Online Appendix.Table 1. Baseline Characteristics of the Patients Stratified Into SYNTAX Score Tertiles
Variable
SYNTAX Score <9
(n  311)
SYNTAX Score >9–16
(n  234)
SYNTAX Score >16
(n  262) p Value
Baseline characteristics
Age, yrs 61.8 11.9 63.3 11.1 66.1 11.7 0.001
Male 234 (75.2) 183 (78.2) 191 (72.9) 0.39
Risk factors
Diabetes 32 (10.3) 29 (12.4) 49 (18.7) 0.01
Hypertension 170 (54.8) 128 (55.2) 156 (59.8) 0.69
Hyperlipidemia 130 (41.8) 88 (37.8) 103 (39.5) 0.91
Current cigarette use 131 (42.1) 92 (39.5) 84 (32.4) 0.07
Creatinine clearance, ml/min 0.003
Median 80.7 81.1 73.1
IQR 63.5–102.6 61.7–102.4 55.3–94.3
Prior myocardial infarction 17 (5.5) 20 (8.6) 27 (10.3) 0.33
Prior percutaneous coronary intervention 13 (4.2) 10 (4.3) 13 (5.0) 0.88
Prior stroke or transient ischemic attack 7 (2.3) 13 (5.6) 14 (5.3) 0.13
Left ventricular ejection fraction*
Median 50 45 42 0.001
IQR 45–55 40–52 35–50
Killip class II 30 (9.7) 32 (13.9) 55 (21.2) 0.001
Heart rate, beats/min
Median 72 75 75 0.06
IQR 60–85 62–89 66–89
Time from onset of symptoms to hospital presentation, min
Median 110 120 107 0.23
IQR 61–180 65–207 65–196
Time from hospital presentation to angioplasty, min†
Median 87 80 90 0.31
IQR 60–122 57–120 60–126
Values are n (%) or mean SD, unless otherwise stated. *Assessed at standard transthoracic echocardiogram at discharge; †calculated as the time difference between first hospital contact and first balloon
inflation.IQR interquartile range.
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69160 to 325 mg orally or 250 mg intravenously, followed by
0 to 125 mg/day orally indefinitely) and clopidogrel (300
g orally and then 75 mg/day for at least 3 months).
YNTAX score. SXscore for each patient was calculated
etrospectively by scoring all coronary lesions with a diam-
ter stenosis 50%, in vessels 1.5 mm, using the SXscore
lgorithm, which is described in full elsewhere (7,11) and is
vailable on the SXscore website (18). All angiographic
ariables pertinent to SXscore calculation were computed by
Table 2. Procedural Results and Use of Medications Stratified Into Tertiles
Variable
SYNTAX Score <9
(n  311)
Extent of disease
Single-vessel disease 195 (62.7)
Double-vessel disease 97 (31.2)
Triple-vessel disease 19 (6.11)
Infarct-related vessel
Left anterior descending coronary artery 87 (28.1)
Left circumﬂex artery 71 (22.9)
Right coronary artery 151 (48.7)
Left main coronary artery 1 (0.3)
Lesion characteristics
Number of diseased lesions
Median 1
IQR 1–2
Range 1–4
1 bifurcation lesion 67 (21.5)
1 occlusion 120 (38.6)
1 tortuous lesion 22 (7.1)
1 lesion 20 mm 70 (22.5)
1 calciﬁed lesion 7 (2.3)
1 lesion with thrombus 65 (20.9)
Procedural characteristics
Number of stents implanted in the culprit lesion
Median 1
IQR 1–1
Range 0–3
Total length of stent in the culprit lesion, mm
Median 18
IQR 18–23
Incomplete revascularization 97 (31.2)
Abciximab therapy* 149 (47.9)
Tiroﬁban therapy† 162 (52.1)
Use of intra-aortic balloon pump 0 (0)
Medications at discharge‡
Number evaluated 309
Aspirin 299 (96.8)
Clopidogrel or ticlopidine 292 (94.5)
Beta-blockers 242 (78.3)
Statins 270 (87.4)
ACE inhibitors 238 (77.0)
Values are n (%) ormean SD, unless otherwise stated. *Two patients whowere randomized to ab
and abciximab; ‡differences in the numbers of patients who were evaluated are due to the deathsACE angiotensin-converting enzyme; other abbreviations as in Table 1.investigators blinded to clinical outcomes (S.G., G.S.). In
he event of disagreement, the opinion of a third investiga-
or was sought, and the final decision was made by
onsensus.
There is currently no validated method of calculating the
Xscore in patients with STEMI as this patient group was
xcluded from the initial SXscore algorithm (7). To over-
ome this, 2 different methods of scoring the infarct-related
rtery (IRA) were investigated in this study. The first
e SYNTAX Score
SYNTAX Score >9–16
(n  234)
SYNTAX Score >16
(n  262) p Value
0.001
111 (47.4) 84 (32.1)
84 (35.9) 90 (34.4)
39 (16.7) 88 (33.6)
0.001
104 (44.8) 169 (65.0)
37 (16.0) 25 (9.6)
90 (38.8) 63 (24.2)
1 (0.4) 3 (1.2)
2 3 0.001
1–3 2–4
1–6 1–7
119 (50.9) 184 (70.2) 0.001
144 (61.5) 210 (80.2) 0.001
23 (9.8) 43 (16.4) 0.001
91 (38.9) 138 (52.7) 0.001
22 (9.4) 67 (25.6) 0.001
64 (27.4) 64 (24.4) 0.21
1 1 0.004
1–1 1–1
0–4 0–4
23 22 0.001
18–28 18–28
159 (67.9) 210 (80.2) 0.001
119 (49.2) 125 (47.7) 0.56
115 (50.9) 137 (52.3)
3 (1.3) 14 (5.4) 0.001
229 254
222 (96.9) 244 (96.1) 0.39
224 (97.8) 245 (96.4) 0.71
182 (79.5) 200 (78.7) 0.90
196 (85.6) 216 (85.0) 0.82
179 (78.2) 203 (79.9) 0.89
weremistakenly treatedwith tirofiban; †1 patient randomized to tirofiban received both tirofiban
nts before discharge.of th
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70ethod (Method A) involved calculating the SXscore using
he current algorithm, with the culprit lesion scored using
he angiographic views of the IRA before any intervention.
herefore, if the IRA was occluded it was scored as an
ccluded artery of 3-months’ duration. The second
ethod (Method B) still used the current scoring algorithm;
owever, the angiographic films just before stent implanta-
ion were used to score the culprit lesion (Fig. 1). Clinical
utcomes according to the SXscore calculated using
ethod B, and a comparison of the 2 different scoring
ethods is reported in the Online Appendix; the SXscores
alculated using Method A are presented in the rest of this
rticle.
AMI score. The PAMI score was selected as a comparative
isk score as only clinical variables such as patient age, Killip
lass, heart rate, diabetic status, and location of myocar-
ial infarction are required for its calculation, in contrast
o the angiographic variable used in the SXscore. The
AMI score was calculated retrospectively using algo-
ithms that are described in detail elsewhere (1). A
ombination of the SXscore (calculated using Method A)
nd the PAMI score, the SX-PAMI score, was also created
s described in the Online Appendix.
tudy end points. The primary end point of this post hoc
tudy was mortality at 1-year follow-up. Secondary end
oints included: reinfarction; clinically driven target vessel
evascularization (TVR), major adverse cardiac events
MACE) (a composite of death, reinfarction, and TVR),
nd stent thrombosis (ST) out to 1-year follow-up. An
ndependent blinded clinical events committee evaluated all
linical end points, and a data and safety monitoring board
nsured the safe conduct of the trial.
eﬁnitions. Complete definitions are provided elsewhere
16,17). Deaths from all causes are reported. Re-infarction
as defined as: 1) 24 h of randomization: recurrent
schemic symptoms with new, persistent ST-segment ele-
Table 3. Clinical Outcomes at 12 Months Stratified Into Tertiles of the SYN
Outcome
SYNTAX score <9
(n  311)
Hierarchical outcomes at 1 yr (n  311)
Death 10 (3.2)
Reinfarction 4 (1.3)
Death or reinfarction 14 (4.5)
MACE* 24 (7.7)
Nonhierarchical outcomes at 1 yr
Reinfarction 4 (1.3)
Target vessel revascularization 11 (3.5)
Deﬁnite ST 1 (0.3)
Deﬁnite or probable ST 2 (0.6)
Deﬁnite or probable or possible ST 4 (1.3)
Values are n (%). *A composite of death, reinfarction and target vessel-revascularization.MACEmajor adverse cardiac events; ST stent thrombosis; other abbreviations as in Table 1.ation 1 mm in 2 contiguous leads or new persistent
T-segment depression1 mm in2 contiguous leads not
ue to changes from evolution of the index STEMI;
) between 24 h and 7 days of randomization: ischemic
ymptoms 20 min and either a creatinine kinase level
twice the upper limit of normal or further elevations
50% above the previous lowest level in patients with
lready elevated enzyme levels; and 3) after 7 days of
andomization: either a typical increase and decrease of
evels of biochemical markers of myocardial necrosis to
reater than the upper limit of normal or, if markers are
lready elevated, further elevation of a marker 50% of the
owest recovery level from the index STEMI with either
schemic symptoms or other ischemic changes on the
lectrocardiogram. Clinically driven TVR was defined as
ny coronary artery bypass graft surgery, or a second PCI of
he original target vessel, driven by clinical symptoms of
yocardial ischemia with either a positive stress test or
lectrocardiographic evidence of ischemic changes at rest
ttributable to the target vessel and the presence of luminal
tenosis of70% of the reference luminal diameter by visual
stimate. A successful PCI was defined as a residual stenosis
30% in the treated vessel with Thrombolysis In Myocar-
ial Infarction (TIMI) coronary flow grade 3. Stent throm-
osis was classified according to the Academic Research
onsortium classification (19).
tatistical analysis. All analyses were conducted according
o the intention-to-treat principle. All variables were strat-
fied according to SXscore tertiles. Discrete data were
ummarized as frequencies (%), whereas parametric contin-
ous data were expressed as mean SD, and nonparametric
ontinuous data were expressed as median (interquartile
ange). The Fisher exact test (categorical variables), 1-way
nalysis of variance test (parametric, continuous variables),
nd Kruskal-Wallis test (nonparametric, continuous vari-
bles) were used to analyze differences between the 3 study
Score
YNTAX score >9–16
(n  234)
SYNTAX Score >16
(n  262) p Value
(n  234) (n  262)
10 (4.3) 24 (9.2) 0.006
6 (2.6) 16 (6.1)
16 (6.8) 40 (15.3) 0.001
31 (13.2) 65 (24.8) 0.001
7 (3.0) 18 (6.9) 0.001
17 (7.3) 32 (12.2) 0.001
2 (0.9) 10 (3.8) 0.002
5 (2.1) 14 (5.3) 0.001
7 (3.0) 18 (6.9) 0.001TAX
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71roups. Event-free survival curves were generated by the
aplan-Meier method, and survival between groups was
ompared using the log-rank test. Cox regression analysis
as used to find independent predictors of mortality,
ACE, and any ST with those variables with a p value of
0.10 in the univariate analysis being included in the
ackward stepwise multivariate model. A reclassification
nalysis was used to compare the SXscore calculated by
ethods A and B, and the SXscore with the SX-PAMI
core, as described in the Online Appendix. Receiver-
perator characteristic (ROC) curves were used to compare
he discrimination of the SXscore, PAMI score, and SX-
AMI score. A 2-sided p value 0.05 was considered
ignificant for all tests. All analyses were performed using
PSS software (version 17.0, SPSS, IBM, Somers, New York).
esults
n total, the STRATEGY and MULTISTRATEGY stud-
es enrolled 945 patients. The SXscore was subsequently
alculated in 807 (85.4%) patients (1,584 lesions); the
rimary reasons for the incomplete dataset were missing
ngiogram compact discs and the presence of coronary
rtery bypass grafts.
YNTAX score. SXscore ranged from 0 to 66, with a mean
D of 13.9 8.6 and a median (interquartile range) of 12.3
11.4). SXscore was not normally distributed (Kolmogorov-
mirnov p  0.05). In this post hoc analysis, patients were
tratified according to approximate SXscore tertiles defined
s: SXLOW 9 (n  311), 9  SXMID 16 (n  234),
XHIGH 16 (n  262).
aseline clinical angiographic and procedural characteristics.
aseline clinical, angiographic, and procedural characteris-
ics stratified according to SXscore tertile are summarized in
ables 1 and 2. Patient age and the incidence of diabetes
ere both significantly higher, whereas left ventricular
unction and creatinine clearance were both significantly
ower in the SXHIGH tertile. In line with its method of
erivation, markers of increased lesion complexity such as
he presence of bifurcation lesions and total occlusions were
ll significantly higher in the SXHIGH tertile.
linical outcomes. Clinical outcomes through to 12-months
ollow-up are shown in Table 3, whereas Kaplan-Meier
umulative curves are shown in Figure 2. Overall, all clinical
utcomes including the primary end point of all-cause
eath; the composite of death/reinfarction; MACE; and
ates of definite, definite/probable, and any ST were all
ignificantly higher in the highest SXscore tertile.
ultivariate analysis. The results of the Cox multivariate
nalysis for death, the composite of MACE and any ST are
hown in Table 4. Following multivariate adjustment, the
Xscore remained an independent predictor of death,Figure 2. Kaplan-Meier Survival Curves
Kaplan-Meier survival curves for (A) death; (B) the composite of death and
reinfarction, and (C) the composite of death, re-infarction and target vessel
revascularization. Patients in the highest SYNTAX score tercile have signiﬁcantlyACE, and any ST at 1-year follow-up.
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72Xscore calculated using Method B. Clinical outcomes and
he results of a Cox multivariate analysis using the SXscore
alculated using Method B are reported in the Online
ppendix, Online Tables 1 and 2, and Online Figure 1. To
ompare both methods of SXscoring, a reclassification
nalysis was also performed and this demonstrated that
ompared with Method A, the SXscore calculated using
ethod B inappropriately reclassified over 12% of patients
or the end point of mortality, and just under 1% of patients
or the end point of MACE. The results of this reclassifi-
ation analysis are provided in full in the Online Appendix
nd Online Tables 3 and 4.
Xscore versus PAMI score. The PAMI score was available
n 791 patients and ranged from 0 to 14, with a mean SD
f 3.9  3.3 and a median (interquartile range) of 3 (5). On
ox multivariate analysis, the PAMI score was an indepen-
ent predictor of mortality and MACE out to 1-year
ollow-up; however, unlike the SXscore, it was only a
nivariate predictor of any ST. The ROC curves and the
espective C-statistics for the SXscore calculated using
ethods A and B, the PAMI score, and SX-PAMI score
or 1-year mortality, mortality/reinfarction, TVR, and
ACE are shown in Figure 3.
X-PAMI score. A reclassification analysis was performed to
ompare the SXscore with the combination SX-PAMI
core for the end points of mortality and MACE. Results
re presented in full in the Online Appendix and Online
ables 5 and 6. In brief, use of the SX-PAMI lead to an
verall net reclassification improvement of 15.7% and 4.6%
Table 4. Univariate and Multivariate Predictors of Death, MACE, and Any S
Variable
Univariate Pr
HR (95% CI)
Death
Creatinine clearance 0.97 (0.96–0.98)
Left ventricular function 0.92 (0.89–0.94)
Male sex 0.51 (0.28–0.94)
PAMI score 1.34 (1.24–1.47)
SYNTAX score 1.05 (1.03–1.08)
Major adverse cardiovascular events
Creatinine clearance 0.99 (0.98–1.00)
Door-to-balloon time 1.01 (1.00–1.02)
Left ventricular function 0.94 (0.92–0.96)
PAMI score 1.17 (1.10–1.23)
Sirolimus-eluting stent use 0.55 (0.38–0.80)
SYNTAX score 1.06 (1.04–1.08)
Any stent thrombosis
Left ventricular function 0.91 (0.87–0.96)
PAMI score 1.25 (1.12–1.39)
SYNTAX score 1.07 (1.04–1.10)
CI confidence interval; HR hazard ratio; PAMI Primary Angioplasty in Myocardial Infarction; oor mortality and MACE, respectively. riscussion
his study represents the first dedicated analysis of the
Xscore in patients with STEMI and demonstrates that the
Xscore does have a utility in the assessment of patients
aving primary PCI, being an independent predictor of
ortality, MACE, and any ST out to 1-year follow-up.
Mechanical revascularization, which is now the preferred
reatment option for patients presenting with STEMI (20)
s virtually always performed using PCI. It follows, there-
ore, that the goal of risk stratification in patients having
rimary PCI is not to determine appropriate treatment
trategy, but more to determine the risk of adverse cardiac
vents after procedure that may guide discharge planning
nd follow-up schedule (5,21), while also serving as a means
or individual operators, institutions, and regulatory bodies
o access and compare performance.
The current study has demonstrated that patients with
igher SXscores, irrespective of whether they are calculated
sing Method A or B, are at increased risk of mortality and
ACE when presenting with STEMI. This is consistent
ith data from the assessment of patients having elective
CI (7–15), and also in line with previous studies of primary
CI that identify variables associated with higher SXscores
uch as TIMI flow grade 3 (21,22), and the presence of
ultivessel disease as significant independent predictors of
ACE (23).
In this current analysis, 2 different methods of applying
he SXscore were investigated as the initial SXscore algo-
rs Multivariate Predictors
p Value HR (95% CI) p Value
0.001
0.001 0.95 (0.92–0.98) 0.003
0.03
0.001 1.15 (1.00–1.09) 0.03
0.001 1.05 (1.00–1.09) 0.02
0.01
0.02
0.001 0.97 (0.95–0.99) 0.001
0.001 1.09 (1.00–1.18) 0.045
0.002 0.64 (0.43–0.98) 0.04
0.001 1.07 (1.04–1.10) 0.001
0.001 0.95 (0.91–0.99) 0.02
0.001 1.13 (0.97–1.30) 0.11
0.001 1.06 (1.02–1.11) 0.008
breviations as in Tables 1 and 3.T
edictoithm did not include any specific reference to patients with
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73TEMI (7). Although both methods of scoring identified
hose patients at highest risk of events, and were indepen-
ent predictors of clinical outcomes, there were some
mportant differences between both scores. Of note, the
Figure 3. Receiver-Operator Characteristic Curves and Corresponding C-Sta
Receiver-operator characteristic curves and corresponding C-statistics for the S
Method B, the PAMI score and the SX-PAMI for (A) death, (B) composite of de
death, re-infarction, and target vessel revascularization. The discriminatory abil
calculated using Method B. Similarly, whilst the discriminatory ability of the SY
and death/re-infarction, it is superior for assessment of target vessel revascular
composite of death, reinfarction, and target vessel revascularization.Xscore calculated using Method B had an inferior discrim- wnatory ability compared with Method A, as well as inap-
ropriately reclassified patients with respect to the end
oints of death and MACE. Although both scores had the
ame range, the mean SXscores calculated using Method A
s for the SYNTAX Score
score calculated using Method A, the SYNTAX score calculated using
d re-infarction, (C) target vessel revascularization and (D) the composite of
the SYNTAX score calculated using Method A is consistently superior to that
score appears inferior to the PAMI and SX-PAMI for the assessment of death
. The combination score, however, is superior for the assessment of thetistic
YNTAX
ath an
ity of
NTAX
izationere significantly higher than those calculated using
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74ethod B (Method A mean: 13.9 vs. Method B mean:
0.3, p  0.05). This partly reflects the weighting factor in
he SXscore algorithm, which gives an occlusion-
ultiplying factor of 5, compared with a multiplier of 2 if
he vessel has a diameter stenosis between 50% and 99%. In
he setting of primary PCI, this important difference in
alculation provides a possible explanation for the inappro-
riate reclassification observed using Method B. Patients
ith pre-PCI TIMI flow grade 0/1 in the IRA have been
hown to have a significantly higher risk of 6-month
ortality compared with those with TIMI flow grade 3
22). It follows that this higher risk is only translated into
igher SXscores calculated using Method A, when the IRA
s scored as an occlusion, and not Method B. It would seem
vident that the calculation of the SXscore in patients
ndergoing primary PCI should be performed using
ethod A.
One of the limitations of using the SXscore for risk
tratification is the absence of clinical variables in its
alculation, a deficiency that can be successfully addressed
hrough its combination with clinical-based risk models
24,25). The present study provides additional evidence to
upport this: first, by demonstrating improvements in the
iscriminatory ability of the SXscore when combined with
he PAMI score, and second, through the observed appro-
riate reclassification of patients following use of the com-
ination score. Despite these modifications, the purely
linical-based PAMI score still had the greatest discrimina-
ory ability for hard clinical end points such as mortality,
ndicating that these outcomes are influenced more by
re-morbid clinical characteristics than by lesion complex-
ty. Consistent with this, Peterson et al. (26) reported only
marginal change in the C-statistic of in-hospital mortality
hen angiographic variables such as lesion class, vessel
ocation, and TIMI flow grade were removed from the
CDR (National Cardiovascular Data Registry) risk score.
ith respect to soft end points such as TVR, the superior
iscriminatory ability of the SXscore may be explained by
he significantly greater risk of TVR in those with incom-
lete revascularization (76.2% vs. 23.8%, p  0.007), which
n turn was significantly related to the initial SXscore.
In view of its high associated morbidity and mortality,
nd unpredictability, ST remains an ongoing concern fol-
owing PCI, particularly following implantation of drug-
luting stent in patients with STEMI (27). The presence of
hrombus can increase the risk of incomplete stent apposi-
ion, which together with delayed healing and a poorer
ompliance to dual antiplatelet therapy are factors impli-
ated in increasing the risk of ST in STEMI patients
28,29). The current analysis demonstrates an important
elationship between SXscore and the risk of ST, which has
reviously been reported in the “all-comers” LEADERS
Limus Eluted From a Durable Versus Erodable Stent
oating) population (14). Importantly, this relationshipay help identify those patients who would benefit from
dditional measures to reduce the risk of ST such as the
ssessment of platelet reactivity, higher loading doses of
lopidogrel, and more intensive counseling regarding com-
liance to dual antiplatelet therapy (30).
tudy limitations. This study is limited by its post-hoc
ature. The ROC method of analysis, although well suited
or diagnostic purposes (31), may not be appropriate for
rognostic models, because these models need to incorpo-
ate the dimension of time, which adds a stochastic element
32). Therefore, it has been suggested that ROC analysis
ethods are not well validated for the assessment of
ime-censored data; however, in the current study, the same
ethods have been used to assess both scoring systems, and
hese methods are consistent with previous published stud-
es evaluating risk models (33). The relatively small sample
ize of the current study reiterates the need to validate the
ndings in a larger patient cohort. Unfortunately, the absence
f relevant data prevented the calculation of a previously
alidated combined angiographic and clinical–based score such
s the CADILLAC score (2). Finally, the role of calculating
he SXscore after revascularization is as yet unexplored, but this
ay well provide important data to help determine which
atients require further revascularization.
onclusions
Xscore does have a role in the risk stratification of patients
ith STEMI having primary PCI; however, this ability can
e improved through a combination that includes clinical
ariables.
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